The Microtubule Cytoskeleton: An Old Validated Target for Novel Therapeutic Drugs

Overview

Journal Front Pharmacol

Date 2022 Oct 3

PMID 36188585

Authors

Laurence Lafanechere

Affiliations

Soon will be listed here.

Abstract

Compounds targeting microtubules are widely used in cancer therapy with a proven efficacy. However, because they also target non-cancerous cells, their administration leads to numerous adverse effects. With the advancement of knowledge on the structure of tubulin, the regulation of microtubule dynamics and their deregulation in pathological processes, new therapeutic strategies are emerging, both for the treatment of cancer and for other diseases, such as neuronal or even heart diseases and parasite infections. In addition, a better understanding of the mechanism of action of well-known drugs such as colchicine or certain kinase inhibitors contributes to the development of these new therapeutic approaches. Nowadays, chemists and biologists are working jointly to select drugs which target the microtubule cytoskeleton and have improved properties. On the basis of a few examples this review attempts to depict the panorama of these recent advances.

Citing Articles

Targeting TUBG1 in RB1-negative tumors.

Lindstrom L, Zhou J, Villoutreix B, Malycheva D, Otrocka M, Gustavsson A FASEB J. 2025; 39(5):e70431.

PMID: 40019206 PMC: 11869804. DOI: 10.1096/fj.202403180RR.

Precise photopharmacological eradication of metastatic tumor cells.

Varady A, Grissenberger S, Wenninger-Weinzierl A, Poplimont H, Sturtzel C, Schmitner N Dis Model Mech. 2025; 18(2).

PMID: 40014051 PMC: 11892682. DOI: 10.1242/dmm.052016.

The Co-Administration of Paclitaxel with Novel Pyridine and Benzofuran Derivatives that Inhibit Tubulin Polymerisation: A Promising Anticancer Strategy.

Peruzynska M, Birger R, Klos P, Kwiecien H, Struk L, Sosnicki J Pharmaceutics. 2025; 17(2).

PMID: 40006590 PMC: 11859455. DOI: 10.3390/pharmaceutics17020223.

Comprehensive multi-omics analysis elucidates colchicine-induced toxicity mechanisms and unveils the therapeutic potential of MLN4924 and kinase inhibitors.

Zhai L, Jia X, Chen Y, Liu M, Zhang J, Ma S Acta Pharmacol Sin. 2024; 46(3):702-714.

PMID: 39567751 PMC: 11845715. DOI: 10.1038/s41401-024-01422-5.

From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies.

Golla U, Patel S, Shah N, Talamo S, Bhalodia R, Claxton D Cancers (Basel). 2024; 16(20).

PMID: 39456548 PMC: 11506385. DOI: 10.3390/cancers16203454.

References

Xiao Q, Xue T, Shuai W, Wu C, Zhang Z, Zhang T . High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design. Biochem Biophys Res Commun. 2020; 534:330-336. DOI: 10.1016/j.bbrc.2020.11.082. View

Noha R, Abdelhameid M, Ismail M, Mohammed M, Salwa E . Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells. Eur J Med Chem. 2020; 209:112870. DOI: 10.1016/j.ejmech.2020.112870. View

Prunier C, Prudent R, Kapur R, Sadoul K, Lafanechere L . LIM kinases: cofilin and beyond. Oncotarget. 2017; 8(25):41749-41763. PMC: 5522193. DOI: 10.18632/oncotarget.16978. View

Komarova Y, Lansbergen G, Galjart N, Grosveld F, Borisy G, Akhmanova A . EB1 and EB3 control CLIP dissociation from the ends of growing microtubules. Mol Biol Cell. 2005; 16(11):5334-45. PMC: 1266430. DOI: 10.1091/mbc.e05-07-0614. View

Kato C, Miyazaki K, Nakagawa A, Ohira M, Nakamura Y, Ozaki T . Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis. Int J Cancer. 2004; 112(3):365-75. DOI: 10.1002/ijc.20431. View

Zhao Z, Xu J, Chen J, Kim S, Reimers M, Bacanu S . Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder. Mol Psychiatry. 2014; 20(5):563-572. PMC: 4326626. DOI: 10.1038/mp.2014.82. View

Park J, Agnihotri S, Golbourn B, Bertrand K, Luck A, Sabha N . Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway. Oncotarget. 2014; 5(19):9382-95. PMC: 4253441. DOI: 10.18632/oncotarget.2412. View

Nieuwenhuis J, Brummelkamp T . The Tubulin Detyrosination Cycle: Function and Enzymes. Trends Cell Biol. 2018; 29(1):80-92. DOI: 10.1016/j.tcb.2018.08.003. View

Janke C, Bulinski J . Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat Rev Mol Cell Biol. 2011; 12(12):773-86. DOI: 10.1038/nrm3227. View

10.

Borisy G, Taylor E . The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein. J Cell Biol. 1967; 34(2):525-33. PMC: 2107313. DOI: 10.1083/jcb.34.2.525. View

11.

Cassimeris L, Spittle C . Regulation of microtubule-associated proteins. Int Rev Cytol. 2001; 210:163-226. DOI: 10.1016/s0074-7696(01)10006-9. View

12.

Gobrecht P, Andreadaki A, Diekmann H, Heskamp A, Leibinger M, Fischer D . Promotion of Functional Nerve Regeneration by Inhibition of Microtubule Detyrosination. J Neurosci. 2016; 36(14):3890-902. PMC: 6705512. DOI: 10.1523/JNEUROSCI.4486-15.2016. View

13.

Little M, Seehaus T . Comparative analysis of tubulin sequences. Comp Biochem Physiol B. 1988; 90(4):655-70. DOI: 10.1016/0305-0491(88)90320-3. View

14.

Li F, Hu Y, Qi S, Luo X, Yu H . Structural basis of tubulin detyrosination by vasohibins. Nat Struct Mol Biol. 2019; 26(7):583-591. PMC: 6609488. DOI: 10.1038/s41594-019-0242-x. View

15.

MacRae T . Tubulin post-translational modifications--enzymes and their mechanisms of action. Eur J Biochem. 1997; 244(2):265-78. DOI: 10.1111/j.1432-1033.1997.00265.x. View

16.

Fromer M, Pocklington A, Kavanagh D, Williams H, Dwyer S, Gormley P . De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014; 506(7487):179-84. PMC: 4237002. DOI: 10.1038/nature12929. View

17.

Muhlethaler T, Milanos L, Ortega J, Blum T, Gioia D, Roy B . Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action. Angew Chem Int Ed Engl. 2022; 61(25):e202204052. PMC: 9324959. DOI: 10.1002/anie.202204052. View

18.

Badin-Larcon A, Boscheron C, Soleilhac J, Piel M, Mann C, Denarier E . Suppression of nuclear oscillations in Saccharomyces cerevisiae expressing Glu tubulin. Proc Natl Acad Sci U S A. 2004; 101(15):5577-82. PMC: 397425. DOI: 10.1073/pnas.0307917101. View

19.

Huang Yang C, Horwitz S . Taxol: The First Microtubule Stabilizing Agent. Int J Mol Sci. 2017; 18(8). PMC: 5578123. DOI: 10.3390/ijms18081733. View

20.

Lyons-Abbott S, Sackett D, Wloga D, Gaertig J, Morgan R, Werbovetz K . α-Tubulin mutations alter oryzalin affinity and microtubule assembly properties to confer dinitroaniline resistance. Eukaryot Cell. 2010; 9(12):1825-34. PMC: 3008275. DOI: 10.1128/EC.00140-10. View